calcitnin
Bisphosphonates, calcitonin, and denosumab are examples of medications that inhibit osteoclast activity by reducing bone resorption. Additionally, a high level of calcium in the blood can also inhibit osteoclast activity.
Yes, parathyroid hormone stimulates osteoclast activity indirectly by increasing the production of RANK-L (receptor activator of nuclear factor kappa-B ligand) from osteoblasts. RANK-L then binds to RANK on osteoclast precursor cells, promoting their differentiation and activation into mature osteoclasts.
Osteoclast activity is decreased when calcitonin is present. Calcitonin inhibits bone resorption by osteoclasts, leading to decreased breakdown of bone tissue.
The removal of calcium from bones by osteoclasts is primarily stimulated by parathyroid hormone (PTH), which is released by the parathyroid glands in response to low blood calcium levels. PTH increases osteoclast activity, leading to bone resorption and the release of calcium into the bloodstream. Additionally, factors such as vitamin D and certain cytokines can also enhance osteoclast activity and contribute to calcium mobilization from bones.
yes
estrogen decreases osteoclast(bone reduction remodeling) which decreases osteoporosis. promotes osteoblast activity in bone formation. keeping calcium in bones and keeping bone density/integrity.
Yes. It is the electrical activity that stimulates the mechanical activity.
osteoclast
because it stimulates growth
Calcitonin is the hormone that inhibits osteoclast activity when blood calcium levels rise above normal. It helps regulate calcium levels in the blood by promoting calcium deposition in bones, thus decreasing blood calcium levels.
because it stimulates growth
Osteoclastic activity increases the blood calcium level. Osteoblastic activity nullify the effect of osteoclastic activity. Both go hand in hand to rearrange the orientation of calcium lines in the bones, as per requirement of the stresses on the bones.